Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent

NCT03367689 ·Status: TERMINATED ·Phase: PHASE2

Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

NCT04251169 ·Status: TERMINATED ·Phase: PHASE2

PF-07104091 as a Single Agent and in Combination Therapy

NCT04553133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

NCT03222856 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

NCT05296746 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

NCT01078662 ·Status: COMPLETED ·Phase: PHASE2

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

NCT03184090 ·Status: COMPLETED ·Phase: PHASE2

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

NCT04603183 ·Status: COMPLETED ·Phase: PHASE2

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

NCT04874025 ·Status: COMPLETED

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

NCT06434610 ·Status: RECRUITING ·Phase: PHASE2

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

NCT04261218 ·Status: COMPLETED ·Phase: PHASE1

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

NCT04318223 ·Status: UNKNOWN ·Phase: PHASE2

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

NCT02494596 ·Status: COMPLETED ·Phase: PHASE1

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

NCT05358639 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer

NCT04494958 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190 ·Status: RECRUITING ·Phase: PHASE2

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

NCT02491983 ·Status: COMPLETED ·Phase: PHASE2

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

NCT05091346 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

NCT07306559 ·Status: RECRUITING ·Phase: PHASE1

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

NCT02611024 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

NCT07002177 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

NCT04288089 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

NCT01407562 ·Status: TERMINATED ·Phase: PHASE1